ZYDELIG® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia - Cancer Therapy Advisor

ZYDELIG® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia

Slideshow

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

This slideshow reviews drug information for ZYDELIG® (idelalisib), indicated for relapsed chronic lymphoma.

Table of Contents

Slide 3: Indication, Dosage, and Administration
Slide 7: Use in Specific Populations
Slide 9: Clinical Pharmacology
Slide 13: Warnings and Precautions
Slide 18: Clinical Safety and Efficacy
Slide 24: Drug Storage and SupplySlide 26: References

Next hm-slideshow in Slides